Drug intelligence / Profile preview

AIP 304

Development stage: Preclinical
Lead developer: AIP
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

AIP 304 is a therapeutic radiopharmaceutical candidate under development by Advanced Innovative Partners (AIP) for the treatment of lung cancer. Currently in the preclinical stage, it is designed as a targeted radionuclide therapy to deliver cytotoxic radiation specifically to lung tumor cells. It is likely intended to be used in a theranostic approach alongside AIP 302, the company's diagnostic imaging agent for lung cancer. As a targeted radionuclide therapy, it aims to provide localized treatment while minimizing damage to surrounding healthy tissues.

Other names: AIP-304-AIP-radiopharmaceutical-Lung Cancer (Therapeutic)

Beyond the preview

Go deeper on AIP 304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP 304.

Explore the full profile